Changes to the Board of Directors

Brisbane, 30 May 2023

QBiotics Group Limited (QBiotics) announces that Mr. Neville Mitchell has resigned as a Non-Executive Director with effect from 31 May 2023. Neville has been a valuable contributor during his 6 years as a Board member of the Company. During most of his tenure, he has also been Chair of the Audit and Risk Management Committee.

Dr. Steven Ogbourne, Executive Director and Chief Translational Research Officer has advised that he will not seek re-election at this year’s Annual General Meeting after serving two terms as a Director. Steve will remain in the Company as a highly valued Executive.

The Board would like to take this opportunity to thank Neville and Steve for their commitment, contributions and service during their time as Directors of QBiotics. Following these changes, the Board will be comprised of four Non-Executive Directors and two Executive Directors. The Directors will consider the appropriate mix of skills on the Board prior to any additional appointments being made to the Board.



JANE LOWE, IR DEPARTMENT or +61 411 117 774



QBiotics is an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics’ business model is to develop products that have applications in both veterinary and human markets. Success in the veterinary programme validates QBiotics technology and de-risks human development while having the potential to generate early revenue.

QBiotics’ lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.

QBiotics’ lead wound healing product is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I/IIa clinical trial in patients with venous leg ulcers.